Sign Out
In patients with moderate or severe renal impairment coadministration of Bilastine with P-glycoprotein inhibitors, such as e.g, ketoconazole, erythromycin, cyclosporine, ritonavir or diltiazem, may increase plasmatic levels of Bilastine and therefore increase the risk of adverse reactions of Bilastine. Therefore, coadministration of Bilastine and P-glycoprotein inhibitors should be avoided in patients with moderate or severe renal impairment.
Effects on ability to drive and use machines: Treatment with Bilastine 20 mg may affect the driving performance. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.
Use in Children: Efficacy and safety of Bilastine in children under 12 years of age have not been established.
